These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32392604)

  • 1. Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia.
    Djambas Khayat C; El Khorassani M; Aytaç S; Harroche A; Dahmane A; Pujol S; Henriet C; de Moerloose P; Bridey F
    Thromb Haemost; 2020 Jun; 120(6):957-967. PubMed ID: 32392604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.
    Djambas Khayat C; El Khorassani M; Lambert T; Gay V; Barthez-Toullec M; Lamazure J; Bellon A; Henriet C; Bridey F; Négrier C
    J Thromb Haemost; 2019 Apr; 17(4):635-644. PubMed ID: 30661302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of fibrinogen concentrate pharmacokinetics and dosing for bleeds and surgery in adults, adolescents, and children with congenital afibrinogenaemia and hypofibrinogenaemia.
    Djambas Khayat C; Lohade SD; Zekavat OR; Kruzhkova I; Solomon C; Knaub S; Peyvandi F
    Haemophilia; 2022 Nov; 28(6):1022-1032. PubMed ID: 35925493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of fibrinogen concentrate.
    Manco-Johnson MJ; Dimichele D; Castaman G; Fremann S; Knaub S; Kalina U; Peyvandi F; Piseddu G; Mannucci P;
    J Thromb Haemost; 2009 Dec; 7(12):2064-9. PubMed ID: 19804533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.
    Ross C; Rangarajan S; Karimi M; Toogeh G; Apte S; Lissitchkov T; Acharya S; Manco-Johnson MJ; Srivastava A; Brand B; Schwartz BA; Knaub S; Peyvandi F
    J Thromb Haemost; 2018 Feb; 16(2):253-261. PubMed ID: 29220876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children.
    Bellon A; Fuseau E; Roumanie O; Lamazure J; Stevens W; Dahmane A; Barthez-Toullec M; Golly D; Henriet C; Bridey F
    Br J Clin Pharmacol; 2020 Feb; 86(2):329-337. PubMed ID: 31658379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-authorization safety study of Clottafact
    Négrier C; Rothschild C; Borg JY; Lambert T; Claeyssens S; Sanhes L; Stieltjes N; Bertrand A; André MH; Sié P; Gruel Y; Tellier Z
    Vox Sang; 2016 Nov; 111(4):383-390. PubMed ID: 27583698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate.
    Négrier C; Rothschild C; Goudemand J; Borg JY; Claeyssens S; Alessi MC; Jaffry AC; Teboul C; Padrazzi B; Waegemans T
    J Thromb Haemost; 2008 Sep; 6(9):1494-9. PubMed ID: 18627444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency.
    Djambas Khayat C; Lohade S; D'Souza F; Shamanur LG; Zekavat OR; Kruzhkova I; Schwartz B; Solomon C; Knaub S; Peyvandi F
    Haemophilia; 2021 Mar; 27(2):283-292. PubMed ID: 33326665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA-02 and FORMA-04 clinical trials.
    Khayat CD; Lohade S; Zekavat OR; Kruzhkova I; Solomon C; Peyvandi F
    Transfusion; 2022 Sep; 62(9):1871-1881. PubMed ID: 35932202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen replacement therapy for congenital fibrinogen deficiency.
    Bornikova L; Peyvandi F; Allen G; Bernstein J; Manco-Johnson MJ
    J Thromb Haemost; 2011 Sep; 9(9):1687-704. PubMed ID: 21711446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial.
    Downey LA; Andrews J; Hedlin H; Kamra K; McKenzie ED; Hanley FL; Williams GD; Guzzetta NA
    Anesth Analg; 2020 Mar; 130(3):740-751. PubMed ID: 31490252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.
    Lissitchkov T; Madan B; Djambas Khayat C; Zozulya N; Ross C; Karimi M; Kavakli K; De Angulo GR; Almomen A; Schwartz BA; Solomon C; Knaub S; Peyvandi F
    Transfusion; 2018 Feb; 58(2):413-422. PubMed ID: 29194665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, efficacy and safety of a novel fibrinogen concentrate in pediatric patients with congenital afibrinogenemia.
    Khayat CD; Navarro-Puerto J; Ross CR; Subramanian K; Kalappanavar NK; Rucker K; Liang W; Mondou E
    Blood Coagul Fibrinolysis; 2023 Jan; 34(1):61-69. PubMed ID: 36484281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding.
    Danés AF; Cuenca LG; Bueno SR; Mendarte Barrenechea L; Ronsano JBM
    Vox Sang; 2008 Apr; 94(3):221-226. PubMed ID: 18179679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency.
    Peyvandi F
    Thromb Res; 2009 Dec; 124 Suppl 2():S9-11. PubMed ID: 20109654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postauthorization safety study of Clottafact
    Négrier C; Ducloy-Bouthors AS; Piriou V; De Maistre E; Stieltjes N; Borel-Derlon A; Colson P; Picard J; Lambert T; Claeyssens S; Boileau S; Bertrand A; André MH; Fourrier F; Ozier Y; Sié P; Gruel Y; Tellier Z
    Vox Sang; 2018 Feb; 113(2):120-127. PubMed ID: 29238971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register.
    Weiss G; Lison S; Glaser M; Herberger S; Johanning K; Strasser T; Huber T; Spannagl M; Heindl B
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):727-34. PubMed ID: 22024795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial.
    Karkouti K; Callum J; Rao V; Heddle N; Farkouh ME; Crowther MA; Scales DC
    BMJ Open; 2018 Apr; 8(4):e020741. PubMed ID: 29678987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.
    Fenger-Eriksen C; Lindberg-Larsen M; Christensen AQ; Ingerslev J; Sørensen B
    Br J Anaesth; 2008 Dec; 101(6):769-73. PubMed ID: 18818192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.